Mesalazine as a new therapeutic option for chronic idiopathic urticaria

Journal of Dermatological Treatment

Volumn 23, Issue 5, 2012, Pages 323-329

  Dastgheib, Ladan ^a   Jowkar, Farideh ^a,c   Abdollahee, Alireza ^a   Namazi, Mohammad Reza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

chronic idiopathic urticaria; dermatology life quality index; Mesalazine

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MESALAMINE; PILOT PROJECTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; URTICARIA; YOUNG ADULT;

EID: 84866301985     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.565015     Document Type: Article

References (27)

1. Najib U, Sheikh J. The spectrum of chronic urticaria. Allergy Asthma Proc 2009;30:1-10.
2. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39:777-787.
3. O'Donnel BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201. (Pubitemid 27062719)
4. Poon E, Seed PT, Greaves MW, et al. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-671. (Pubitemid 29191386)
5. Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc 2008;29:439-46.
6. Lourenço FD, Azor MH, Santos JC, Prearo E, Maruta CW, Rivitti EA, et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release. Br J Dermatol 2008; 158(5):979-986. (Pubitemid 351521459)
7. Młynek A, Maurer M, Zalewska A. Update on chronic urticaria: focusing on mechanisms. Curr Opin Allergy Clin Immunol 2008;8(5):433-437.
8. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):316-320. (Pubitemid 43381808)
9. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 2. Ann Allergy Asthma Immunol 2008;100(6):517-26; quiz 526-528, 544. (Pubitemid 351829849)
10. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 1. Ann Allergy Asthma Immunol 2008;100(5):403-411; quiz 412-414, 468.
11. Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995;74(2):155-9.
12. McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006;142(10): 1337-1342. (Pubitemid 44583285)
13. Sweetman SC. Martindale: The complete drug reference, 36th ed. London: Pharmaceutical Press; 2009.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-216. (Pubitemid 24194579)
15. Lennox RD, Leahy MJ. Validation of the dermatology life quality index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004;93(2): 142-146. (Pubitemid 39128493)
16. Finlay AY, Khan GK. Dermatology life quality index. Available at: http://www.dermatology.org.uk/downloads/dlqifarsi. doc.
17. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004;4:8.
18. Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;154(3):533-538. (Pubitemid 43382664)
19. Bharti R. Mesalazine in treatment of psoriasis. Indian J Dermatol Venereol Leprol 1996;62:231-232. (Pubitemid 127042809)
20. Di Lorenzo G, Pacor ML, Mansueto P, Esposito-Pellitteri M, Ditta V, Lo Bianco C, et al. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006;31(3):327-334.
21. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-14. (Pubitemid 37174711)
22. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95(12): 3452-3457.
23. Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995;272(1):399-406.
24. Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, PunchardNA, Thompson RP. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 1993;34(2):252-6. (Pubitemid 23049122)
25. Punchard NA, Greenfield SM, Thompson RPH. Mechanism of action of 5-aminosalicylic acid. Mediators Inflamm 1992; 1(3):151-165.
26. Haskó G, Szabó C, Németh ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001;103(4):473-478. (Pubitemid 32744394)
27. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991;36(2): 179-184.